Belimumab ameliorates symptoms and disease activity in patients with dermatomyositis and juvenile dermatomyositis refractory to standard therapy: A retrospective observational study
- 1 May 2024
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (3) , 524-527
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- National Key Research and Development Program of China Stem Cell and Translational Research
- Changsha Science and Technology Bureau
- Hunan Provincial Natural Science Foundation
- Department of Science and Technology of Hunan Province
This publication has 5 references indexed in Scilit:
- Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort studyRheumatology, 2019
- Elevated serum B‐cell activating factor levels in patients with dermatomyositis: Association with interstitial lung diseaseThe Journal of Dermatology, 2019
- Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North AmericaPediatric Rheumatology, 2017
- Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximabRheumatology, 2016
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialArthritis & Rheumatism, 2012